0:00 0:00 1x

This is read by an automated voice. Please report any issues or inconsistencies here .

Trump administration negotiated a deal with drugmakers Eli Lilly and Novo Nordisk to expand Medicare coverage for obesity drugs Zepbound and Wegovy.

Medicare patients will pay $50 copays and starting doses of new pill forms will cost $149 monthly, down from unaffordable $500 prices.

The agreement addresses a longstanding affordability barrier; many patients have struggled to continue paying for treatments they need indefinitely to maintain weight loss.

President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy.

The drugs are part of a new generation of obe

See Full Page